Eli Lilly has paid US$150 M upfront as part of a collaboration with Nektar Therapeutics to co-develop NKTR-358, a Phase I T-cell regulator that could potentially act on a wide range of inflammatory and autoimmune disorders. Lilly has been signing a number of licensing and collaboration agreements to expand its pipeline since it suffered patent expirations on some of its key drugs.